Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 17Genitourinary 6Thoracic 5Gastrointestinal 5Lymphoid 4Dermatologic 4Gynecologic 3CNS 3Sarcoma 2Myeloid 2Head & Neck 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Endocrine 1Classical hematology 1

Conditions

Multiple Myeloma 30Hodgkin Disease 17Leukemia, Lymphocytic, Chronic, B-Cell 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Myelodysplastic Syndromes 14Lymphoma, Non-Hodgkin 13Leukemia, Myeloid, Acute 13Myeloproliferative Disorders 11Lymphoma, Mantle-Cell 11Primary Myelofibrosis 10Neoplasms, Plasma Cell 10Lymphoma, Large B-Cell, Diffuse 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Waldenstrom Macroglobulinemia 9Lymphoma, Follicular 9Lymphoma 9Leukemia 9Graft vs Host Disease 9Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myelomonocytic, Chronic 8Burkitt Lymphoma 8Myelodysplastic-Myeloproliferative Diseases 7Leukemia, Prolymphocytic 7Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 7Leukemia, Myeloid, Accelerated Phase 7Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large-Cell, Anaplastic 6Leukemia, Myeloid, Chronic-Phase 6Blast Crisis 6Lymphoma, T-Cell, Cutaneous 5

Interventions

Cyclophosphamide 8Zoledronic Acid 5Therapeutics 5Flow Cytometry 5pembrolizumab 3fludarabine 3Specimen Handling 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Immunologic Techniques 3Gemcitabine 3Amplified Fragment Length Polymorphism Analysis 3venetoclax 2trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2liposomal doxorubicin 2liposomal amphotericin B 2dabrafenib 2copanlisib 2aldesleukin 2abiraterone 2Vorinostat 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Rituximab 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Sirolimus × Plasma cell × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡